Inovio Pharmaceuticals: A Long Shot Investment!
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced that it is pausing enrolment for an ongoing late-stage study evaluating its lead COVID-19 vaccine candidate INO-4800, as lab tests show that the candidate had significantly lower levels of antibodies against the Omicron variant. The Company is now planning changes...
